Amphetamine-induced chorea in attention deficit-hyperactivity disorder

Movement Disorders

Volumn 19, Issue 7, 2004, Pages 840-842

  Morgan, John C ^a   Winter, W Christopher ^b   Wooten, G Frederick ^b  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

ADHD; Amphetamine; Chorea

Indexed keywords

AMPHETAMINE; DIAZEPAM; DIPHENHYDRAMINE; ESCITALOPRAM; LORAZEPAM; METHYLPHENIDATE;

ADULT; ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; CASE REPORT; CHOREA; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DEPRESSION; DRUG RESPONSE; HUMAN; LABORATORY DIAGNOSIS; MALE; PRIORITY JOURNAL; TIC; TREATMENT OUTCOME;

ADULT; AMPHETAMINES; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHOREA; HUMANS; MALE; METHYLPHENIDATE;

EID: 4344695187     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.20081     Document Type: Article

References (36)

1. Spencer T, Biederman J, Wilens T, et al. Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 2001;58:775-782.
2. Barkley RA. Major life activity and health outcomes associated with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2002;63(Suppl. 12):10-15.
3. Adler LA, Chua HC. Management of ADHD in adults. J Clin Psychiatry 2002;63(Suppl. 12):29-35.
4. Wilens TE, Spencer TJ, Biederman J. A review of the pharmacotherapy of adults with attention deficit/hyperactivity disorder. J Atten Disord 2002;5:189-202.
5. Weiner WJ, Sanchez-Ramos J. Movement disorders and dopaminomimetic stimulant drugs. In: Lang AE, Weiner WJ, editors. Drug-induced movement disorders. Mt. Kisco, New York: Futura Publishing Co., Inc; 1992. p 315-337.
6. Lipkin PH, Goldstein IJ, Adesman AR. Tics and dyskinesias associated with stimulant treatment in attention-deficit hyperactivity disorder. Arch Pediatr Adolesc Med 1994;148:859-861.
7. Efron D, Jarman F, Barker M. Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial. Pediatrics 1997;100:662-666.
8. Varley CK, Vincent J, Varley P, Calderon R. Emergence of tics in children with attention deficit hyperactivity disorder treated with stimulant medications. Compr Psychiatry 2001;42:228-233.
9. Tourette's Syndrome Study Group. Treatment of ADHD in children with tics. Neurology 2002;58:527-536.
10. Pascual-Leone A, Dhuna A. Cocaine-associated multifocal tics. Neurology 1990;40:999-1000.
11. Cardoso FE, Jankovic J. Cocaine-related movement disorders. Mov Disord 1993;8:175-178.
12. Rhee KJ, Albertson TE, Douglas JC. Choreoathetoid disorder associated with amphetamine-like drugs. Am J Emerg Med 1988; 6:131-133.
13. Lundh H, Tunving K. An extrapyramidal choreiform syndrome caused by amphetamine addiction. J Neurol Neurosurg Psychiatry 1981;44:728-730.
14. Bartzokis G, Beckson M, Wirshing DA, et al. Choreoathetoid movements in cocaine dependence. Biol Psychiatry 1999;45:1630-1635.
15. Leys D, Destee A, Petit H, Warot P. Chorea associated with oral contraception. J Neurol 1987;235:46-48.
16. Rylander G. Psychoses and the punding and choreiform syndromes in addiction to central stimulant drugs. Psychiatr Neurol Neurochir 1972;75:203-212.
17. Prinzmetal M, Bloomberg W. The use of benzedrine for the treatment of narcolepsy. JAMA 1935;105:2051-2054.
18. Bray GA. Use and abuse of appetite-suppressant drugs in the treatment of obesity. Ann Intern Med 1993;119:707-713.
19. Mattson RH, Calverley JR. Dextroamphetamine-sulfate induced dyskinesias. JAMA 1968;204:108-110.
20. Weiner WJ, Nausieda PA, Klawans HL. Methylphenidate-induced chorea: case report and pharmacologic implications. Neurology 1978;28:1041-1044.
21. Seeman P, Madras B. Methylphenidate elevates resting dopamine Which lowers the impulse-triggered release of dopamine: a hypothesis. Behav Brain Res 2002;130:79-83.
22. Winsberg B, Matinsky S, Kupietz S, Richardson E. Is there dose-dependent tolerance associated with chronic methylphenidate therapy in hyperactive children? Oral dose and plasma considerations. Psychopharmacol Bull 1987;23:107-110.
23. Ross DC, Fischhoff J, Davenport B. Treatment of ADHD when tolerance to methylphenidate develops. Psychiatr Serv 2002;53: 102.
24. Solanto MV. Clinical psychopharmacology of AD/HD: implications for animal models. Neurosci Biobehav Rev 2000;24:27-30.
25. Klawans HL, Weiner WJ. The effect of d-amphetamine on choreiform movement disorders. Neurology 1974;24:312-318.
26. Nausieda PA, Bieliauskas LA, Bacon LD, et al. Chronic dopaminergic sensitivity after Sydenham's chorea. Neurology 1983;33: 750-754.
27. Fox GC, Ebeid S, Vincenti G. Paroxetine-induced chorea. Br J Psychiatry 1997;170:193-194.
28. Bharucha KJ, Sethi KD. Complex movement disorders induced by fluoxetine. Complex movement disorders induced by fluoxetine. Mov Disord 1996;11:324-326.
29. Nielsen AS, Mors O. Choreiform dyskinesias with acute onset and protracted course following fluoxetine treatment. J Clin Psychiatry 1999;60:868-869.
30. Bradbury AJ, Costall B, Naylor RJ, Onaivi ES. 5-Hydroxytryptamine involvement in the locomotor activity suppressant effects of amphetamine in the mouse. Psychopharmacology (Berl) 1987;93: 457-465.
31. Kuczenski R, Segal DS. Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. J Neurochem 1997;68:2032-2037.
32. Rebec GV, Alloway KD, Curtis SD. Apparent serotonergic modulation of the dose-dependent biphasic response of neostriatal neurons produced by d-amphetamine. Brain Res 1981;210:277-289.
33. Dewey SL, Smith GS, Logan J, et al. Serotonergic modulation of striatal dopamine measured with positron emission tomography (PET) and in vivo microdialysis. J Neurosci 1995;15:821-829.
34. Tiihonen J, Kuoppamaki M, Nagren K, et al. Serotonergic modulation of striatal D2 dopamine receptor binding in humans measured with positron emission tomography. Psychopharmacology (Berl) 1996;126:277-280.
35. Arnt J, Overo KF, Hyttel J, Olsen R. Changes in rat dopamine- and serotonin function in vivo after prolonged administration of the specific 5-HT uptake inhibitor, citalopram. Psychopharmacology (Berl) 1984;84:457-465.
36. Kameda K, Kusumi I, Suzuli K, et al. Effects of citalopram on dopamine D2 receptor expression in the rat brain striatum. J Mol Neurosci 2000;14:77-86.